The development of CNS-active LRRK2 inhibitors using property-directed optimisation
Authors:
- Munikumar Reddy DoddareddyMDMunikumar Reddy Doddareddy
- Michael KassiouMKMichael Kassiou
Open Access
- 1 July 2013
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (13) , 3690-3696
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of parkinson diseaseNeuroToxicology, 2011
- Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson’s Disease-Related Toxicity in Human NeuronsACS Chemical Biology, 2011
- The Parkinson's disease marketNature Reviews Drug Discovery, 2011
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyThe Lancet Neurology, 2008
- Etiology and Pathophysiology of Frontotemporal Dementia, Parkinson Disease and Alzheimer Disease: Lessons from Genetic StudiesNeurodegenerative Diseases, 2008
- Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's DiseaseNeuron, 2004
- Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic PathologyNeuron, 2004
- A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1Annals of Neurology, 2002
- Diagnostic Criteria for Parkinson DiseaseArchives of Neurology, 1999
- History of levodopa and dopamine agonists in Parkinson's disease treatmentNeurology, 1998